EHT 0202: Phase IIa data

Top-line data from 159 patients with mild to moderate AD in a double-blind, placebo-controlled, French Phase IIa trial showed that 40 or 80 mg oral EHT 0202 twice daily in combination with an acetylcholinesterase inhibitor for 3 months was well tolerated, meeting the studies primary safety endpoint. There were no treatment-related gastrointestinal, cardiovascular or biological adverse events, which the company said suggests that EHT 0202 does not clinically interact with acetylcholinesterase inhibitors. ...